Parkinson’s is the fastest growing neurological condition in the world and affects around 153,000 people in the UK.

Scientists have identified the melatonin MT1 receptor as a key regulator of REM sleep, crucial for memory, dreaming, and ...

BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative ...

Detroit Tigers legend Kirk Gibson will be joined by members of the Kirk Gibson Foundation for Parkinson’s Board of Directors ...

A new study finds sleeping on your back could increase your risk for neurodegenerative disorders, such as Alzheimer’s disease ...

Parkinson's comes on slowly, and diagnosing the often-devastating movement disorder, particularly in its early stages, ...

We look forward to strengthening our relationship with Sanofi as the VTX3232 clinical programs progress, with data from the Phase 2a trial in patients with early Parkinson’s disease and data from the ...

At first, Jonel suspected she was experiencing symptoms of Parkinson’s disease as she had seen her father’s experience with ...

A first-of-its-kind study will use ultrasound and light therapies to investigate targeted treatment of Alzheimer’s disease, ...

Parkinson's disease (PD) affects about 2% of people aged 70 and older. Over the next 20 years, the number of individuals with ...

Exercise is known as one of the best weapons in limiting the effects of the disease and creating dopamine that is low for ...

A novel drug molecule could potentially lead to new treatments to prevent Parkinson's disease in younger patients, according to new research.